



## Short communication

# Simultaneous HPLC analysis of pseudophedrine hydrochloride, codeine phosphate, and triprolidine hydrochloride in liquid dosage forms

Adnan Manassra<sup>a,\*</sup>, Mustafa Khamis<sup>a</sup>, Magdy el-Dakiky<sup>a</sup>, Zuhair Abdel-Qader<sup>b</sup>, Fuad Al-Rimawi<sup>a</sup>

<sup>a</sup> Faculty of Science and Technology, Al-Quds University, P.O. Box 20002, East Jerusalem, Palestine

<sup>b</sup> Research and Development Department, Jerusalem Pharmaceutical Co., P.O. Box 3570, Al-Bireh, Palestine

## ARTICLE INFO

## Article history:

Received 23 June 2009

Received in revised form 3 October 2009

Accepted 30 October 2009

Available online 10 November 2009

## Keywords:

HPLC

Pseudophedrine hydrochloride

Codeine phosphate

Triprolidine hydrochloride

Capacity factor

## ABSTRACT

An HPLC method using UV detection is proposed for the simultaneous determination of pseudophedrine hydrochloride, codeine phosphate, and triprolidine hydrochloride in liquid formulation. C18 column (250 mm × 4.0 mm) is used as the stationary phase with a mixture of methanol:acetate buffer:acetonitrile (85:5:10, v/v) as the mobile phase. The factors affecting column separation of the analytes were studied. The calibration graphs exhibited a linear concentration range of 0.06–1.0 mg/ml for pseudophedrine hydrochloride, 0.02–1.0 mg/ml for codeine phosphate, and 0.0025–1.0 mg/ml for triprolidine hydrochloride for a sample size of 5 µl with correlation coefficients of better than 0.999 for all active ingredients studied. The results demonstrate that this method is reliable, reproducible and suitable for routine use with analysis time of less than 4 min.

© 2009 Elsevier B.V. All rights reserved.

## 1. Introduction

The combination of pseudophedrine hydrochloride, codeine phosphate, and triprolidine hydrochloride is used in pharmaceutical preparations as cough–cold syrup. This combination, however, is not present in USP or BP. In this respect, a method for the analysis of this combination is needed. In the scientific literature, analysis of pseudophedrine hydrochloride, codeine phosphate, and triprolidine hydrochloride has been reported as individual ingredients and in combination products. Analytical methods have included gas–liquid chromatography (GLC) [1], UV [2–6], thin layer chromatography (TLC) [7], and HPLC [8–26]. Codeine phosphate in combination with other compounds has been determined in different pharmaceutical preparations by GLC [1], TLC [7], UV [2–3], and HPLC [8–10,14,16–18,20–26]. Pseudophedrine hydrochloride in combination with other compounds has been determined in different pharmaceutical preparations by HPLC [11,15,18]. Pseudophedrine hydrochloride and triprolidine hydrochloride was simultaneously determined in different pharmaceutical dosage forms by HPLC [12–13]. Pseudophedrine hydrochloride and codeine phosphate was also determined simultaneously by HPLC [19]. All of the above mentioned methods, however, have not been employed for the simultaneous determination of pseudophedrine hydrochloride, codeine phosphate, and triprolidine hydrochloride

in any pharmaceutical formulation. In this work, we introduce an HPLC method for simultaneous determination of this combination in liquid formulation. Validation of the current method will be performed according to the requirements of USP for assay determination which include accuracy, precision, selectivity, linearity and range.

## 2. Experimental

### 2.1. Equipments and setting

The system used was a Merck Hitachi HPLC (Hitachi, Ltd. Tokyo, Japan) equipped with manual loop injector and connected to a variable diode array wavelength detector and recorder. A C18 reversed-phase column (250 mm × 4.0 mm i.d) bonded onto 5 µm silica gel manufactured by Merck was used for the analysis. The flow rate was 1.5 mL min<sup>-1</sup>, wavelength was 254 nm; and the injection volume was 5 µL.

### 2.2. Reagents

All chemicals were of analytical grade and used without further purification. Water was distilled and deionised by passing through water purification system. Acetonitrile and methanol HPLC grade are from J.T. Baker (NJ, USA). Ammonium acetate is from Merck (Darmstadt, Germany). The active ingredients pseudophedrine HCl, codeine phosphate, triprolidine HCl, and the excipients used in manufacturing the liquid syrup

\* Corresponding author. Tel.: +970 22796961; fax: +970 296960.

E-mail address: [amanassra@yahoo.com](mailto:amanassra@yahoo.com) (A. Manassra).

were supplied by Jerusalem Pharmaceuticals Co. Ltd., Al-Bireh, Palestine.

### 2.3. Standards and sample preparation

The mobile phase used after optimisation was a mixture of methanol:acetate buffer:acetonitrile with a ratio of (85:5:10, v/v), respectively. A buffer solution (pH = 6.9) was prepared by dissolving 20.0 g ammonium acetate in 200.0 mL distilled water. The mobile phase was filtered using 0.45  $\mu\text{m}$  microporous polyamide filters and was degassed with the aid of a sonicator (Fisher Scientific, FS220).

Standard solution of the three active ingredients of the drug was prepared in the following manner: 150 mg of pseudophedrine hydrochloride and 50 mg of codeine phosphate were dissolved in 50 mL methanol (solution 1). 12.5 mg of triprolidine hydrochloride was dissolved in 50 mL methanol (solution 2) 10 mL of the first solution, and 5 mL of the second solution were diluted to 50 mL with methanol.

Sample solution of the drug was prepared by diluting 5.0 mL of the syrup to 50.0 mL with methanol, to get a concentration equal to the concentration of the analytes in the standard solution, i.e. 0.6  $\text{mg mL}^{-1}$  of pseudophedrine hydrochloride, 0.2  $\text{mg mL}^{-1}$  of codeine phosphate, and 0.025  $\text{mg mL}^{-1}$  of triprolidine hydrochloride. The solutions were filtered through a 0.45- $\mu\text{m}$  membrane before use.

### 2.4. Solutions for validation study

#### 2.4.1. Linearity and range

Stock standard of pseudophedrine hydrochloride with a concentration of 1.0  $\text{mg mL}^{-1}$  was prepared by dissolving 100 mg of pseudophedrine hydrochloride in 100 mL of methanol. Nine different concentrations of pseudophedrine hydrochloride was prepared in the following manner: 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 4.0, 6.0, and 8.0 mL of the stock standard was diluted to 10 mL with methanol to get the following concentrations: 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.4, 0.6, and 0.8  $\text{mg mL}^{-1}$  of pseudophedrine hydrochloride. The same procedure was repeated for codeine phosphate and triprolidine hydrochloride.

#### 2.4.2. Accuracy (recovery)

For recovery study, 100 mL of simulated syrup was prepared by dissolving 600 mg pseudophedrine hydrochloride, 200 mg codeine phosphate, and 25 mg of triprolidine hydrochloride in the required excipients of the drug formulation. A tenfold dilution was performed, and 10  $\mu\text{L}$  were injected into the column. The peak areas resulting were compared with that of the standard.

The standard of the three active ingredients (prepared in Section 2.3) was used for precision study, while the sample of the syrup (also prepared in Section 2.3) was used for intermediate-precision and selectivity studies.

## 3. Results and discussion

### 3.1. Method development

Reversed-phase LC-method was employed in the current work for the separation of these three analytes. To this end, reversed-phase C8 and C18 columns using a mixture of organic solvents (acetonitrile, and methanol) and aqueous buffer as a mobile phase were tested. While C8 column does not show enough resolution between these analytes, C18 column shows adequate resolution (resolution factor is 2.0 between pseudophedrine hydrochloride and codeine phosphate, and 2.5 between codeine phosphate and




Fig. 1. Plot of the capacity factor,  $k'$ , versus concentration of ammonium acetate (g/200 mL water) in the mobile phase. (■) Tripiprodilidne hydrochloride, (◆) codeine phosphate, (▲) pseudophedrine hydrochloride, (●) solvent.

triprolopidine hydrochloride). In order to optimise the chromatographic parameters, the effect of changing the composition of mobile phase on the capacity factor ( $k'$ ) was studied. Results have shown that the capacity factors of the three analytes were decreased with increasing percentage of methanol and acetonitrile in the mobile phase (data not shown), which is expected for reversed-phase LC mode. The capacity factors were also decreased with increasing the concentration of ammonium acetate in the buffer (Fig. 1) as the peaks of the three analytes become sharper with lower retention times and consequently lower capacity factors. Therefore, the selection of the concentration of ammonium acetate in buffer and the composition of mobile phase was based on providing good baseline, adequate separation, and sharp peaks in reasonable time. A typical chromatogram of standard solution containing each of the components listed above is shown in Fig. 2.

### 3.2. Method validation

After method development, validation of the current method was performed in accordance with USP requirements for assay determination (Category-I: analytical methods for quantitation of active ingredients in finished pharmaceutical products) which include accuracy, precision, selectivity, linearity and range.

#### 3.2.1. Linearity and range

To evaluate linearity of the method, ten different concentrations of the three analytes in the range of 0.06–1.00  $\text{mg mL}^{-1}$




Fig. 2. A typical chromatogram of pharmaceutical combination contains 0.3  $\text{mg mL}^{-1}$  pseudophedrine hydrochloride, 0.1  $\text{mg mL}^{-1}$  codeine phosphate, and 0.0125  $\text{mg mL}^{-1}$  triprolopidine hydrochloride. Column: C18 (25 cm  $\times$  4.0 mm). Mobile phase: methanol:acetate buffer pH 6.9:acetonitrile (85:5:10, v/v). Flow rate: 1.5  $\text{mL min}^{-1}$ , wavelength: 254 nm. P: pseudophedrine hydrochloride, CP: codeine phosphate, T: triprolopidine hydrochloride.

**Table 1**  
Intermediate-precision of the method (% of the three active ingredients during 6 days).

Day	Pseudoephedrine hydrochloride (% <sup>a</sup> )	Codeine phosphate (% <sup>a</sup> )	Tripolidine hydrochloride (% <sup>a</sup> )
1	103 ± 0.4	97.2 ± 0.6	96.3 ± 2.0
2	101 ± 1.3	97.5 ± 1.5	96.5 ± 1.9
3	102 ± 1.1	98.5 ± 0.9	97.5 ± 1.7
4	101 ± 0.9	97.1 ± 1.2	96.8 ± 1.8
5	101 ± 1.5	96.8 ± 1.9	97.7 ± 1.2
6	102 ± 0.9	97.5 ± 1.3	97.2 ± 1.5

<sup>a</sup> Mean ± R.S.D. for five samples.

for pseudoephedrine hydrochloride, 0.02–1.0 mg mL<sup>-1</sup> for codeine phosphate and 0.0025–1.0 mg mL<sup>-1</sup> of triprolidine hydrochloride were analysed and the linearity between the peak area and the concentration was examined for each analyte. The results obtained show that the linearity range is 0.06–1.0 mg mL<sup>-1</sup> for pseudoephedrine hydrochloride with a correlation coefficient of 0.9996, 0.02–1.0 mg mL<sup>-1</sup> for codeine phosphate with a correlation coefficient of 0.9997, and 0.0025–1.0 mg mL<sup>-1</sup> for triprolidine hydrochloride with a correlation coefficient of 0.9993.

### 3.2.2. Accuracy (recovery)

Percentage recovery of the three active ingredients using this method was determined using the simulated syrup sample which prepared in experimental part. Results have shown that the mean recovery is 99.8%, 99.4%, and 98.6% for pseudoephedrine hydrochloride, codeine phosphate, and triprolidine hydrochloride, respectively, and the R.S.D. for 6 samples is lower than 1.0%.

### 3.2.3. Precision

Precision of this method was determined by injecting the standard solution of the three analytes six times. The R.S.D. of peak area of six replicates was found to be less than 1.0%.

Intermediate-precision of the method was also evaluated by analyzing five samples of the three analytes at different days (6 days). Results which are represented in Table 1 show good intermediate-precision of the method (average percentage of pseudoephedrine hydrochloride for the 6 days is 102% with a R.S.D. of 0.7%, while it is 97.5% for codeine phosphate with a R.S.D. of 0.6%, and 97.0% for triprolidine hydrochloride with a R.S.D. of 0.6%).

### 3.2.4. Selectivity

Selectivity of the current method was demonstrated by good separation of the three active ingredients (pseudoephedrine hydrochloride, codeine phosphate, and triprolidine hydrochloride). Furthermore, matrix components, e.g. excipients, do not interfere with the three analytes as they have no absorbance.

## 4. Conclusion

This method represents a fast analytical procedure for the simultaneous quantitation of pseudoephedrine hydrochloride, codeine phosphate, and triprolidine hydrochloride. The sample preparation is simple, the analysis time is short and the elution is isocratic. The method is amenable to the analysis of large numbers of samples with excellent precision and accuracy.

## Acknowledgement

The authors appreciate the generous support and cooperation of Jerusalem Pharmaceuticals Company during this research study.

## References

- [1] K. Masumoto, Y. Tashiro, K. Matsumoto, A. Yoshida, M. Hirayama, S. Hayashi, Simultaneous determination of Codeine and Chlorpheniramine in human plasma by capillary column gas chromatography, *J. Chromatogr.* 381 (1986) 323–329.
- [2] M.A. Elsayed, S.F. Belal, A.M. Elwailly, H. Abdine, Spectrophotometric determination of acetaminophen, salicylamide and codeine phosphate in tablets, *Analyst* 104 (1979) 620–625.
- [3] A. Biswas, Spectrophotometric method for determination of Chlorpheniramine maleate in pharmaceutical preparations in the presence of Codeine phosphate and pseudoephedrine Hydrochloride, *Analyst* 105 (1980) 353–358.
- [4] V. Gupta, S.G. Kaskhedikar, Simultaneous spectrophotometric determination of broxetine HCl and pseudo ephedrine HCl in tablet dosage form, *East. Pharm.* 42 (1999) 115–118.
- [5] P. Trivedi, A. Sachan, Simultaneous spectrophotometric estimation of triprolidine HCl and phenyl propylamine HCl, *East. Pharm.* 42 (1999) 107–112.
- [6] R. Moharna, N. Kawathekar, S.C. Chaturvedi, Simultaneous Spectrophotometric estimation of triprolidine HCl and Pseudoephedrine HCl in pharmaceutical dosage form, *Indian J. Pharm. Sci.* 58 (1996) 93–95.
- [7] H.N. Al-Kaysi, M.S. Salem, Simultaneous quantitative determination of codeine phosphate, chlorpheniramine maleate, phenylephrine hydrochloride and acetaminophen in pharmaceutical dosage forms using thin layer chromatography densitometry, *Anal. Lett.* 19 (1986) 915–924.
- [8] N. Muhammad, J.A. Bodnar, Quantitative determination of guaifenesin, phenylpropranolamine hydrochloride, sodium benzoate and codeine phosphate in cough syrups by HPLC, *J. Liq. Chromatogr.* 3 (1980) 113–122.
- [9] W.R. Sisco, C.T. Rittenhouse, L.A. Everhart, Simultaneous HPLC stability-indicating analysis of acetaminophen and codeine phosphate in tablets and capsules, *J. Chromatogr.* 348 (1985) 253–263.
- [10] W.R. Sisco, C.T. Rittenhouse, L.A. Everhart, A.M. McLaughlin, Simultaneous HPLC stability-indicating analysis of acetaminophen, codeine phosphate, and sodium benzoate in elixirs, *J. Chromatogr.* 354 (1986) 355–366.
- [11] T.A. Biemer, Simultaneous analysis of acetaminophen, pseudoephedrine HCl and chlorpheniramine maleate in a cold tablet using an isocratic, mixed micellar HPLC mobile phase, *J. Chromatogr.* 410 (1987) 206–210.
- [12] M.J. Khan, S. Khan, M.A. Salam, HPLC assay for the determination of paracetamol, pseudoephedrine HCl and triprolidine HCl in pharmaceutical preparations, *J. Pharm. Sci.* 6 (1993) 29–34.
- [13] M.J. Akhtar, S. Khan, H. Mushtaq, HPLC assay for the determination of paracetamol, pseudoephedrine HCl and triprolidine HCl, *J. Pharm. Biomed. Anal.* 12 (1994) 379–382.
- [14] O. Lau, C. Mok, HPLC determination of active ingredients in cough–cold syrups with indirect conductometric detection, *J. Chromatogr. A.* 693 (1995) 45–54.
- [15] T.G. Altuntas, Quantitative determination of acrivastine and pseudoephedrine HCl in pharmaceutical formulation by HPLC and derivative spectrophotometer, *J. Pharm. Biomed. Anal.* 17 (1998) 103–109.
- [16] S. Suezene, C. Akay, S. Cevheroglu, Simultaneous determination of guaifenesin and codeine phosphate in tablets by high-performance liquid chromatography, *Il Farmaco* 54 (1999) 705–709.
- [17] S.Y. Liu, S.O. Woo, M.J. Holmes, H.L. Koh, LC and LC–MS–MS analyses of undeclared codeine in antiasthmatic Chinese proprietary medicine, *J. Pharm. Biomed. Anal.* 22 (2000) 481–486.
- [18] M.L. Wilcox, J.T. Stewart, HPLC determination of guaifenesin with selected medications on underivatized silica with an aqueous-organic mobile phase, *J. Pharm. Biomed. Anal.* 23 (2000) 909–916.
- [19] R. Ragonese, M. Mulholland, J. Kalman, Full and fractionated experimental designs for robustness testing in the high-performance liquid chromatographic analysis of codeine phosphate, pseudoephedrine hydrochloride and chlorpheniramine maleate in pharmaceutical preparation, *J. Chromatogr. A* 870 (2000) 45–51.
- [20] M. Kartal, LC method for the analysis of paracetamol, caffeine and codeine phosphate in pharmaceutical preparations, *J. Pharm. Biomed. Anal.* 26 (2001) 857–864.
- [21] M.L. Altun, T. Ceyhan, M. Kartal, T. Atay, N. Oezdemir, S. Cevheroglu, LC method for the analysis of acetylsalicylic acid, caffeine and codeine phosphate in pharmaceutical preparations, *J. Pharm. Biomed. Anal.* 25 (2001) 93–101.
- [22] T. Degin, C. Akay, K. Burykafsar, Simultaneous determination of codeine and ethyl morphine HCl in tablet formulation using liquid chromatography, *J. Pharm. Biomed. Anal.* 26 (2001) 15–21.
- [23] D.H. Hoo, H.Y. Cheung, a chromatographic method for rapid and simultaneous analysis of codeine phosphate, ephedrine HCl and chlorpheniramine in cough–cold syrup formulation, *J. Pharm. Biomed. Anal.* 30 (2003) 1595–1601.
- [24] G.B. Golubitskii, E.V. Budko, Quantitative analysis of complex antipyretic, analgesic, and antidiarrheal drugs by gradient HPLC techniques, *Pharm. Chem. J.* 40 (2006) 633–637.
- [25] A. Schmidt, Validated HPLC method for the determination of residues of acetaminophen, caffeine, and codeine phosphate on swabs collected from pharmaceutical manufacturing equipment in support of cleaning validation, *J. Liq. Chromatogr. Rel. Technol.* 29 (2006) 1663–1673.
- [26] Q. Liao, Y. Deng, Z. Xie, B. Pan, L. Zhang, Rapid simultaneous determination of codeine and morphine in plasma using LC–ESI–MS–MS: application to a clinical pharmacokinetic study, *J. Sep. Sci.* 32 (2009) 202–211.